Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 2/20 | 0.74 |
| ▸ | NPC1 | O15118 | 3/20 | 0.60 |
| ▸ | DRD2 | P14416 | 1/20 | 0.57 |
| ▸ | DRD4 | P21917 | 1/20 | 0.57 |
| ▸ | DRD3 | P35462 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14410497 | 0.83 | L3MBTL1 (0.73) | NPC1DRD2DRD4DRD3KMT2A | |
| SCHEMBL15904029 | 0.83 | RECQL (0.72) | RECQLKMT2AHPGDMEN1TSHR | |
| SCHEMBL1108079 | 0.83 | KMT2A (0.67) | NPC1KMT2AHPGDHTTHDAC1 | |
| SCHEMBL10389706 | 0.82 | NPC1 (0.67) | NPC1DRD2DRD4DRD3KMT2A | |
| SCHEMBL9317853 | 0.80 | RECQL (0.90) | RECQLNPC1KMT2AHPGDMEN1 | |
| SCHEMBL21595955 | 0.80 | NPC1 (0.73) | NPC1DRD2DRD4DRD3KMT2A | |
| SCHEMBL21480863 | 0.79 | RECQL (0.88) | RECQLKMT2AHPGDHDAC1MEN1 | |
| SCHEMBL12223549 | 0.79 | L3MBTL1 (0.62) | RECQLNPC1KMT2AHPGDHTT | |
| SCHEMBL171846 | 0.78 | MTNR1A (0.75) | NPC1DRD2DRD4DRD3KMT2A | |
| SCHEMBL16351169 | 0.78 | HPGD (0.54) | RECQLNPC1KMT2AHPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8092661-B2 | Electropolymerisable monomers, soluble in an aqueous solution and comprising a metalloporphyrin | BIOMERIEUX (FR) | 2012-01-10 | — | — | US | disclosed |
| US-20090314660-A1 | Novel Electropolymerisable Monomers, Soluble in an Aqueous Solution and Comprising a Metalloporphyrin | BIOMERIEUX (FR) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090314660-A1 | Novel Electropolymerisable Monomers, Soluble in an Aqueous Solution and Comprising a Metalloporphyrin | EPS15, PPOX, ACR | RECQL 4683/4885NPC1 4862/4885DRD2 1586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.